GRI Bio (NASDAQ: GRI) Participates in Virtual Investor "What This Means" Segment

Marc Hertz, PhD, CEO of GRI Bio underscores importance of the interim data from their ongoing Phase 2a biomarker study for Idiopathic Pulmonary Fibrosis (IPF) About GRI Bio, Inc. As part of this "What This Means" segment, Marc Hertz, PhD, Chief Executive Officer of GRI Bio discusses the interim data and what this means for its ongoing IPF program, GRI-0621. Watch the "What This Means" video here. GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fi ...